Fresenius Medical Care (FMS) has released an update.
Fresenius Medical Care has reported progress in its financial performance for the second quarter of 2024, with a 2.3% organic revenue growth and improved operating income margins, largely driven by its Care Enablement sector. The company has achieved EUR 57 million in additional FME25 savings, positioning it to potentially reach the higher end of its annual savings goal. Despite divestitures impacting revenue, Fresenius reaffirms its financial outlook for the year, signaling confidence in their strategic trajectory.
For further insights into FMS stock, check out TipRanks’ Stock Analysis page.
